OptiNose, which is commercializing a drug-device nasal spray for chronic rhinosinusitis, raised $120 million by offering 7.5 million shares at $16, within the range of $15 to $17. It had previously planned to offer 6.3 million shares. OptiNose plans to list on the Nasdaq under the symbol OPTN. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as lead managers on the deal.
